ABSTRACT
It is widely held that upright faces are processed more holistically than inverted faces and that this difference is reflected in the face inversion effect. It is not clear, however, how the inversion effect can best be measured, whether it is task specific, or even whether it specifically correlates with processing of upright faces. We examined these questions in a large sample (N = 420) who provided data on processing of upright and inverted stimuli in two different tasks with faces and one with objects. We find that the inversion effects are task dependent, and that they do not correlate better among face processing tasks than they do across face and object processing tasks. These findings were obtained regardless of whether inversion effects were measured by means of difference scores or regression. In comparison, only inversion effects based on regression predicted performance with upright faces in tasks other than those the inversion effects were derived from. Critically, however, inversion effects based on regression also predicted performance with inverted faces to a similar degree as they predicted performance with upright faces. Consequently, and contrary to what is commonly assumed, inversion effects do not seem to capture effects specific to holistic processing of upright faces. While the present findings do not bring us closer to an understanding of which changes in cognitive processing are induced by inversion, they do suggest that inversion effects do not reflect a unitary construct; an implicit assumption that seems to characterize much of the research regarding face processing.
Subject(s)
Facial Recognition , HumansABSTRACT
The effect of the selective serotonin reuptake inhibitor paroxetine on diabetic neuropathy symptoms was examined in comparison to imipramine and placebo in a randomised, double-blind, cross-over study. Paroxetine was given as a fixed dose of 40 mg/day, while the dose of imipramine was adjusted to yield optimal plasma levels of imipramine plus desipramine of 400-600 nM. Paroxetine significantly reduced the symptoms of neuropathy as measured by both observer- and self-rating, but was somewhat less effective than imipramine. However, patients showing a weaker response to paroxetine than to imipramine had lower plasma concentrations of paroxetine than patients with similar response to the 2 drugs. On imipramine 5 patients dropped out because of intolerable side effects and 4 of 19 patients completing the study reported withdrawal symptoms after discontinuing imipramine. On paroxetine no patients dropped out due to side effects and no withdrawal symptoms were reported. Self-rating showed no depressive symptoms at baseline, and no changes during the study. Neither paroxetine nor imipramine caused changes in objective measures of peripheral nerve function. In conclusion, 40 mg paroxetine/day significantly reduced the symptoms in peripheral diabetic neuropathy, and it was suggested that by dose adjustment on the basis of drug level monitoring, paroxetine may become as effective as imipramine. Paroxetine was devoid of the often disturbing autonomic side effects limiting the use of imipramine in several patients.
